Alnylam Pharmaceuticals Inc
ALNY251.560USD
+8.949+3.69%
Handelsschluss 04/25, 16:00（ET）Kurse um 15 Minuten verzögert
32.53BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Alnylam Pharmaceuticals Inc Unternehmen
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.
Unternehmensinformationen
Unternehmens-codeALNY
Name des UnternehmensAlnylam Pharmaceuticals Inc
IPO-datumMay 28, 2004
Gegründet am2003
CEODr. Yvonne L. Greenstreet, M.D.
Anzahl der mitarbeiter2230
WertpapierartOrdinary Share
GeschäftsjahresendeMay 28
Addresse675 W Kendall St
StadtCAMBRIDGE
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl02142-1168
Telefon16175518200
Websitehttps://www.alnylam.com/
Unternehmens-codeALNY
IPO-datumMay 28, 2004
Gegründet am2003
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Phillip A. (Phil) Sharp, Ph.D.
Dr. Phillip A. (Phil) Sharp, Ph.D.
Independent Director
Independent Director
266.90K
--
Dr. Yvonne L. Greenstreet, M.D.
Dr. Yvonne L. Greenstreet, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
99.04K
+16.58%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
47.81K
+40.80%
Mr. Tolga Tanguler
Mr. Tolga Tanguler
Chief Commercial Officer
Chief Commercial Officer
28.01K
+95.27%
Mr. Michael W. (Mike) Bonney
Mr. Michael W. (Mike) Bonney
Chief Compliance Officer, Director
Chief Compliance Officer, Director
20.03K
--
Dr. Dennis A. Ausiello, M.D.
Dr. Dennis A. Ausiello, M.D.
Independent Director
Independent Director
3.64K
--
Dr. Margaret A. Hamburg, M.D.
Dr. Margaret A. Hamburg, M.D.
Independent Director
Independent Director
136.00
--
Ms. Colleen F. Reitan
Ms. Colleen F. Reitan
Independent Director
Independent Director
--
--
Ms. Amy W. Schulman, J.D.
Ms. Amy W. Schulman, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Carolyn R. Bertozzi, M.D.
Ms. Carolyn R. Bertozzi, M.D.
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Phillip A. (Phil) Sharp, Ph.D.
Dr. Phillip A. (Phil) Sharp, Ph.D.
Independent Director
Independent Director
266.90K
--
Dr. Yvonne L. Greenstreet, M.D.
Dr. Yvonne L. Greenstreet, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
99.04K
+16.58%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
47.81K
+40.80%
Mr. Tolga Tanguler
Mr. Tolga Tanguler
Chief Commercial Officer
Chief Commercial Officer
28.01K
+95.27%
Mr. Michael W. (Mike) Bonney
Mr. Michael W. (Mike) Bonney
Chief Compliance Officer, Director
Chief Compliance Officer, Director
20.03K
--
Dr. Dennis A. Ausiello, M.D.
Dr. Dennis A. Ausiello, M.D.
Independent Director
Independent Director
3.64K
--
Umsatzaufteilung
Währung: USDUpdate-Zeit: Sun, Apr 6
Währung: USDUpdate-Zeit: Sun, Apr 6
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
AMVUTTRA
970.45M
43.16%
Regeneron Pharmaceuticals
302.80M
13.47%
GIVLAARI
255.87M
11.38%
ONPATTRO
252.86M
11.25%
OXLUMO
167.05M
7.43%
Other
299.22M
13.31%
Nach RegionUSD
Name
Umsatz
Anteil
United States
933.54M
41.52%
Europe
516.30M
22.96%
Net revenues from collaborations
510.22M
22.69%
Rest of World
196.39M
8.74%
Royalty revenue
91.79M
4.08%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
AMVUTTRA
970.45M
43.16%
Regeneron Pharmaceuticals
302.80M
13.47%
GIVLAARI
255.87M
11.38%
ONPATTRO
252.86M
11.25%
OXLUMO
167.05M
7.43%
Other
299.22M
13.31%
Aktionäre
Update-Zeit: Fri, Feb 21
Update-Zeit: Fri, Feb 21
Aktionärsstatistik
Art
Aktionärsstatistik
Aktionäre
Anteil
Capital World Investors
12.76%
The Vanguard Group, Inc.
10.04%
Fidelity Management & Research Company LLC
9.95%
Capital Research Global Investors
5.36%
BlackRock Institutional Trust Company, N.A.
5.19%
Other
56.70%
Aktionärsstatistik
Aktionäre
Anteil
Capital World Investors
12.76%
The Vanguard Group, Inc.
10.04%
Fidelity Management & Research Company LLC
9.95%
Capital Research Global Investors
5.36%
BlackRock Institutional Trust Company, N.A.
5.19%
Other
56.70%
Art
Aktionäre
Anteil
Investment Advisor
56.07%
Investment Advisor/Hedge Fund
32.20%
Corporation
3.44%
Hedge Fund
2.58%
Sovereign Wealth Fund
1.97%
Pension Fund
1.43%
Bank and Trust
1.19%
Research Firm
1.07%
Individual Investor
0.43%
Institutionelle Beteiligung
Update-Zeit: Sun, Jan 19
Update-Zeit: Sun, Jan 19
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q1
1235
131.13M
100.81%
-458.58K
2024Q4
1263
130.73M
100.99%
-1.47M
2024Q3
1225
126.90M
98.51%
-1.26M
2024Q2
1183
123.30M
96.32%
+1.12M
2024Q1
1172
117.88M
93.23%
-5.46M
2023Q4
1169
120.70M
96.18%
-5.54M
2023Q3
1125
121.55M
96.89%
-6.15M
2023Q2
1119
122.11M
98.30%
-6.32M
2023Q1
1116
123.13M
99.37%
-5.56M
2022Q4
1103
122.98M
99.27%
-3.16M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Capital World Investors
16.60M
12.76%
+92.10K
+0.56%
Dec 31, 2024
The Vanguard Group, Inc.
13.06M
10.04%
+378.83K
+2.99%
Mar 31, 2025
Fidelity Management & Research Company LLC
12.94M
9.95%
-1.20M
-8.49%
Dec 31, 2024
Capital Research Global Investors
6.97M
5.36%
+1.72M
+32.89%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
6.75M
5.19%
+149.81K
+2.27%
Dec 31, 2024
Regeneron Pharmaceuticals Inc
4.44M
3.42%
+4.44M
--
Dec 31, 2024
T. Rowe Price Investment Management, Inc.
4.38M
3.37%
+1.25M
+39.67%
Dec 31, 2024
Wellington Management Company, LLP
4.20M
3.23%
-756.72K
-15.28%
Dec 31, 2024
Baillie Gifford & Co.
4.04M
3.11%
-846.74K
-17.33%
Dec 31, 2024
Dodge & Cox
3.54M
2.72%
-82.27K
-2.27%
Dec 31, 2024
Mehr Anzeigen
Verbundene ETFs
Update-Zeit: Sun, Apr 6
Update-Zeit: Sun, Apr 6
Name
Anteil
Tema Neuroscience and Mental Health ETF
4.39%
VanEck Biotech ETF
4.19%
Global X Genomics & Biotechnology ETF
3.91%
ProShares Ultra Nasdaq Biotechnology
3.49%
First Trust NYSE Arca Biotechnology Index Fund
3.23%
iShares Biotechnology ETF
3.11%
Invesco Nasdaq Biotechnology ETF
3.05%
Franklin Genomic Advancements ETF
2.56%
American Century Focused Dynamic Growth ETF
2.52%
SPDR S&P Biotech ETF
2.5%
Mehr Anzeigen
Tema Neuroscience and Mental Health ETF
Anteil4.39%
VanEck Biotech ETF
Anteil4.19%
Global X Genomics & Biotechnology ETF
Anteil3.91%
ProShares Ultra Nasdaq Biotechnology
Anteil3.49%
First Trust NYSE Arca Biotechnology Index Fund
Anteil3.23%
iShares Biotechnology ETF
Anteil3.11%
Invesco Nasdaq Biotechnology ETF
Anteil3.05%
Franklin Genomic Advancements ETF
Anteil2.56%
American Century Focused Dynamic Growth ETF
Anteil2.52%
SPDR S&P Biotech ETF
Anteil2.5%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten